Back

GLP-1 receptor agonists as an opportunity for patients with atherosclerotic cardiovascular disease as well as obesity in Germany

1 September 2025 (12:30 - 13:15)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (4) - Secondary prevention Secondary Prevention ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Vera Oettinger

University Medical Center Freiburg, Freiburg (Germany)

10 More presentations in this session

Presentation thumbnail
Presentation thumbnail
Doctor L. Heitmann (Reykjavik, IS)
Abstract Slides Video
Presentation thumbnail
Doctor A. Maloberti (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Mrs L. Corteville (Manchester, GB)
Abstract Slides Video
Presentation thumbnail
Professor M. Vrablik (Prague, CZ)
Abstract Slides Video

Access the full session

Session thumbnail
New perspectives in cardiology (4) - Secondary prevention

The Event

Event poster

ESC Congress 2025

1 September 2025 12:30 CET
You may be interested in
thumbnail
Congress Presentation
Percentage and main features of patients referred to a cardiac rehabilitation program who would have an indication for a GLP1 receptor agonist based on the SELECT trial criteria
thumbnail
Congress Presentation
Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes
thumbnail
Congress Presentation
Exploring the preventive role of GLP-1 receptor agonists in reducing pulmonary hypertension in diabetes: a multimodal analysis

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources